UA75864C2 - Prolactin-inhibiting agent - Google Patents

Prolactin-inhibiting agent Download PDF

Info

Publication number
UA75864C2
UA75864C2 UA2001053311A UA2001053311A UA75864C2 UA 75864 C2 UA75864 C2 UA 75864C2 UA 2001053311 A UA2001053311 A UA 2001053311A UA 2001053311 A UA2001053311 A UA 2001053311A UA 75864 C2 UA75864 C2 UA 75864C2
Authority
UA
Ukraine
Prior art keywords
medicinal product
ring
reducing
prolactin levels
compound
Prior art date
Application number
UA2001053311A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Bionorica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionorica Ag filed Critical Bionorica Ag
Publication of UA75864C2 publication Critical patent/UA75864C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/36—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.4.0) system, e.g. naphols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
UA2001053311A 1998-11-19 1999-05-11 Prolactin-inhibiting agent UA75864C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853476A DE19853476A1 (de) 1998-11-19 1998-11-19 Prolaktin-senkendes Mittel
PCT/EP1999/008507 WO2000030623A2 (fr) 1998-11-19 1999-11-05 Agent abaissant la teneur en prolactine

Publications (1)

Publication Number Publication Date
UA75864C2 true UA75864C2 (en) 2006-06-15

Family

ID=7888392

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001053311A UA75864C2 (en) 1998-11-19 1999-05-11 Prolactin-inhibiting agent

Country Status (14)

Country Link
US (2) US6635672B1 (fr)
EP (1) EP1131061B1 (fr)
JP (1) JP4290889B2 (fr)
KR (1) KR100609765B1 (fr)
CN (1) CN1172664C (fr)
AT (1) ATE296623T1 (fr)
BR (1) BR9915514A (fr)
DE (2) DE19853476A1 (fr)
EA (1) EA004588B1 (fr)
ES (1) ES2241373T3 (fr)
HK (1) HK1037523A1 (fr)
PT (1) PT1131061E (fr)
UA (1) UA75864C2 (fr)
WO (1) WO2000030623A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076748A2 (fr) * 2004-02-13 2005-08-25 Janakiram Chodavarapu Composition therapeutique et methode servant a preparer cette composition a partir de dodonaea sp
CN101948473B (zh) * 2006-05-23 2012-10-03 山东绿叶制药有限公司 新的neo-克罗烷型二萜化合物及其应用
EP2556829B1 (fr) 2011-08-10 2015-08-19 Universität Leipzig Diterpènes de labdane bicycliques à utiliser dans le traitement des maladies associées au TRPC6
WO2013072332A1 (fr) * 2011-11-14 2013-05-23 Givaudan Sa Procédés d'utilisation d'antagonistes de récepteurs du goût amer
CN103553919B (zh) * 2013-11-05 2014-12-31 成都中医药大学 一种萜类化合物及其制备方法和用途
CN103804330A (zh) * 2014-02-25 2014-05-21 中国药科大学 ent-半日花烷二萜衍生物的制备及抗肿瘤用途
CN105085449B (zh) * 2014-05-13 2019-03-26 上海中医药大学 半日花型二萜衍生物及其制备方法和应用
CN106565641B (zh) * 2016-11-14 2019-04-02 中国科学院昆明植物研究所 呋喃半日花烷二萜衍生物及其药物组合物和其在制药中的应用
EP3498306A1 (fr) 2017-12-16 2019-06-19 Bionorica SE Extraits de vitex agnus castus destinés au traitement et au diagnostic du cancer du sein
CN110305082A (zh) * 2019-08-21 2019-10-08 成都格利普生物科技有限公司 采用蔓荆子提取蔓荆呋喃的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883074A (en) * 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US6150381A (en) * 1998-06-09 2000-11-21 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor

Also Published As

Publication number Publication date
JP2003521457A (ja) 2003-07-15
EA004588B1 (ru) 2004-06-24
EP1131061B1 (fr) 2005-06-01
WO2000030623A3 (fr) 2000-08-31
WO2000030623A2 (fr) 2000-06-02
US20040138297A1 (en) 2004-07-15
PT1131061E (pt) 2005-08-31
EP1131061A1 (fr) 2001-09-12
JP4290889B2 (ja) 2009-07-08
US6635672B1 (en) 2003-10-21
DE59912125D1 (de) 2005-07-07
EA200100564A1 (ru) 2001-10-22
KR20010080965A (ko) 2001-08-25
CN1172664C (zh) 2004-10-27
ATE296623T1 (de) 2005-06-15
ES2241373T3 (es) 2005-10-16
CN1326343A (zh) 2001-12-12
DE19853476A1 (de) 2000-05-31
KR100609765B1 (ko) 2006-08-09
BR9915514A (pt) 2001-08-07
HK1037523A1 (en) 2002-02-15

Similar Documents

Publication Publication Date Title
Abdelhalim et al. Antidepressant, anxiolytic and antinociceptive activities of constituents from Rosmarinus officinalis
Leeya et al. Hypotensive activity of an n-butanol extract and their purified compounds from leaves of Phyllanthus acidus (L.) Skeels in rats
Ye et al. Brazilein, an important immunosuppressive component from Caesalpinia sappan L.
Ma et al. Antimalarial compounds from Grewia bilamellata
Sándor et al. Evidence supports tradition: The in vitro effects of roman chamomile on smooth muscles
UA75864C2 (en) Prolactin-inhibiting agent
Su et al. Chemical composition and cytotoxic activities of petroleum ether fruit extract of fruits of Brucea javanica (Simarubaceae)
Zaki et al. Isolation of cytotoxic active compounds from Reichardia tingitana with investigation of apoptosis mechanistic induction: In silico, in vitro, and SAR studies
Zhu et al. 4-Hydroxybenzyl alcohol derivatives and their sedative–hypnotic activities
Lahrita et al. Quassinoids in Brucea javanica are potent stimulators of lipolysis in adipocytes
Dereli et al. Identification of the main active antidepressant constituents in a traditional Turkish medicinal plant, Centaurea kurdica Reichardt
Qin et al. New labdane diterpenoids from Leonurus japonicus and their anti-inflammatory activity
Su et al. Activity-guided isolation of novel norwithanolides from deprea s ubtriflora with potential cancer chemopreventive activity
Dell’Agli et al. Inhibition of NF-kB and metalloproteinase-9 expression and secretion by parthenolide derivatives
Mogue et al. Two new polyhydroxylated pentacyclic triterpenes with cytotoxic activities from Manilkara pellegriniana (Sapotaceae)
Wu et al. A caryophyllane-type sesquiterpene, caryophyllenol A from Valeriana amurensis
Wasfi et al. Antiinflammatory activity of some medicinal plants of the United Arab Emirates
Pavlović et al. Chloroform extract of underground parts of Ferula heuffelii: secondary metabolites and spasmolytic activity
CN105669605A (zh) 一种新的二萜类化合物及其制备方法和医药用途
Atilaw et al. 3-Oxo-14α, 15α-epoxyschizozygine: A new schizozygane indoline alkaloid from Schizozygia coffaeoides
Wang et al. Anti-depressant-like effect of curculigoside isolated from Curculigo orchioides Gaertn root
CN111233808A (zh) 一种新双黄酮类化合物及其制备方法和用途
KR20150134554A (ko) 사자발쑥으로부터 추출된 유파폴린과 유파티린을 포함하는 염증 완화 및 피부암 예방용 화장료 조성물
Islam et al. Phytochemical investigations of Campsis radicans L.
CN110882239B (zh) 萜内酯类化合物的镇痛用途